Related Experiment Videos
[Expression of galectin-3 in invasive prolactinomas]
Hong Wang1, Ming-dong Wang, Wen-bin Ma
1Department of Neurosurgery, Affiliated Hospital of Hebei Medical College for Continuous Education, Baoding 071000, China.
Summary
Galectin-3 (Gal-3) is expressed in both invasive and non-invasive prolactinomas, with higher levels in invasive types. This suggests Gal-3 may indicate prolactinoma invasiveness and prognosis.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Context:
- Prolactinomas are pituitary tumors that secrete prolactin.
- Tumor invasiveness affects patient prognosis and treatment strategies.
- Galectin-3 (Gal-3) is a protein implicated in tumor progression.
Purpose:
- To investigate the expression levels of Gal-3 in prolactinomas.
- To determine if Gal-3 expression correlates with tumor invasiveness.
Summary:
- Gal-3 expression was assessed in 16 invasive and 16 non-invasive prolactinomas using immunohistochemistry.
- Gal-3 was detected in all tumor types.
- Significantly higher Gal-3 expression was observed in invasive prolactinomas compared to non-invasive ones (P < 0.05).
Impact:
- Gal-3 expression may serve as a valuable biomarker for assessing prolactinoma invasiveness.
- Elevated Gal-3 levels could indicate a poorer prognosis for prolactinoma patients.
- This finding may guide clinical decisions regarding treatment and monitoring.